^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Glioma
    Drug:temozolomide (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NICE
    Title:

    Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)

    Published date:
    04/26/2001
    Excerpt:
    "Temozolomide is recommended as an option for treating malignant glioma...showing recurrence or progression after standard therapy only if the person has a Karnofsky performance status score greater than or equal to 70 and a life expectancy of 12 weeks or more."
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Excerpt:
    Adult glioma: WHO Grade I...Recurrent or Progressive disease...Other Recommended Regimens...RT + adjuvant TMZ...RT + concurrent and adjuvant TMZ...TMZ
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Lancet Oncol
    Title:

    Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

    Published date:
    05/14/2021
    Excerpt:
    This randomised, open-label, phase 3…newly diagnosed 1p/19q non-co-deleted anaplastic gliomas…temozolomide (12 4-week cycles of 150-200 mg/m2 temozolomide given on days 1-5), or radiotherapy with both concurrent and adjuvant temozolomide…By contrast, adjuvant temozolomide improved overall survival compared with no adjuvant temozolomide…
    DOI:
    10.1016/S1470-2045(21)00090-5
    Trial ID:
    CATNON